Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine - Oregon, June 2021-December 2022
COVID-19 vaccination has been associated with myocarditis in adolescents and young adults, and concerns have been raised about possible vaccine-related cardiac fatalities in this age group. In April 2021, cases of myocarditis after COVID-19 vaccination, particularly among young male vaccine recipients, were reported to the Vaccine Adverse Event Reporting System. To assess this possibility, investigators searched death certificates for Oregon residents aged 16-30 years who died during June 2021-December 2022 for cardiac or undetermined causes of death. For identified decedents, records in Oregon's immunization information system were reviewed for documentation of mRNA COVID-19 vaccination received ≤100 days before death. Among 1,292 identified deaths, COVID-19 was cited as the cause for 30. For 101 others, a cardiac cause of death could not be excluded; among these decedents, immunization information system records were available for 88, three of whom had received an mRNA COVID-19 vaccination within 100 days of death. Of 40 deaths that occurred among persons who had received an mRNA COVID-19 vaccine dose, three occurred ≤100 days after vaccination. Two of these deaths were attributed to chronic underlying conditions; the cause was undetermined for one. No death certificate attributed death to vaccination. These data do not support an association between receipt of mRNA COVID-19 vaccine and sudden cardiac death among previously healthy young persons. COVID-19 vaccination is recommended for all persons aged ≥6 months to prevent COVID-19 and complications, including death.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
---|---|
Enthalten in: |
MMWR. Morbidity and mortality weekly report - 73(2024), 14 vom: 11. Apr., Seite 317-320 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liko, Juventila [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.15585/mmwr.mm7314a5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370922123 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370922123 | ||
003 | DE-627 | ||
005 | 20240415233741.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240412s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.15585/mmwr.mm7314a5 |2 doi | |
028 | 5 | 2 | |a pubmed24n1376.xml |
035 | |a (DE-627)NLM370922123 | ||
035 | |a (NLM)38602888 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Liko, Juventila |e verfasserin |4 aut | |
245 | 1 | 0 | |a Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine - Oregon, June 2021-December 2022 |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.04.2024 | ||
500 | |a Date Revised 15.04.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a COVID-19 vaccination has been associated with myocarditis in adolescents and young adults, and concerns have been raised about possible vaccine-related cardiac fatalities in this age group. In April 2021, cases of myocarditis after COVID-19 vaccination, particularly among young male vaccine recipients, were reported to the Vaccine Adverse Event Reporting System. To assess this possibility, investigators searched death certificates for Oregon residents aged 16-30 years who died during June 2021-December 2022 for cardiac or undetermined causes of death. For identified decedents, records in Oregon's immunization information system were reviewed for documentation of mRNA COVID-19 vaccination received ≤100 days before death. Among 1,292 identified deaths, COVID-19 was cited as the cause for 30. For 101 others, a cardiac cause of death could not be excluded; among these decedents, immunization information system records were available for 88, three of whom had received an mRNA COVID-19 vaccination within 100 days of death. Of 40 deaths that occurred among persons who had received an mRNA COVID-19 vaccine dose, three occurred ≤100 days after vaccination. Two of these deaths were attributed to chronic underlying conditions; the cause was undetermined for one. No death certificate attributed death to vaccination. These data do not support an association between receipt of mRNA COVID-19 vaccine and sudden cardiac death among previously healthy young persons. COVID-19 vaccination is recommended for all persons aged ≥6 months to prevent COVID-19 and complications, including death | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
700 | 1 | |a Cieslak, Paul R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t MMWR. Morbidity and mortality weekly report |d 1984 |g 73(2024), 14 vom: 11. Apr., Seite 317-320 |w (DE-627)NLM012594334 |x 1545-861X |7 nnns |
773 | 1 | 8 | |g volume:73 |g year:2024 |g number:14 |g day:11 |g month:04 |g pages:317-320 |
856 | 4 | 0 | |u http://dx.doi.org/10.15585/mmwr.mm7314a5 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 73 |j 2024 |e 14 |b 11 |c 04 |h 317-320 |